The regulatory landscape in the United Arab Emirates is undergoing significant transformation, with the country continuing to strengthen and centralise oversight of healthcare products through the **Emirates Drug Establishment> (EDE). Recent developments in 2026 highlight the UAE’s broader strategy to modernise healthcare regulation, improve efficiency, and position the country as a leading regional hub for healthcare innovation and market access. For medical device and pharmaceutical...

International regulatory collaboration continues to play an increasingly important role in accelerating access to innovative healthcare technologies. In May 2026, the Health Sciences Authority of Singapore and China’s National Medical Products Administration signed a renewed Memorandum of Understanding (MOU), expanding their long-standing partnership in health product regulation. The updated agreement signals a stronger commitment to regulatory cooperation, innovation, and the development of...

Saudi Arabia continues to enhance its regulatory framework for medical devices, with recent updates reinforcing the importance of accurate product classification and compliance. In early 2026, the Saudi Food and Drug Authority introduced updated product classification guidance, providing clearer requirements for how products are categorised and regulated within the Kingdom. This development reflects Saudi Arabia’s broader ambition to establish a more structured, transparent, and...